FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
4D Molecular Therapeutics, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Netherlands | – | – | – | – | – | – | $0 | $1.00K | $42.00K | $272.00K | $567.00K | $1.81M | – | – |
| United States | – | – | – | – | $33.00K | $23.00K | $37.00K | – | – | – | – | $20.18M | – | – |
From the segment and revenue-disaggregation notes of 4D Molecular Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.